Surendra M, et al. - Safety, as well as efficacy of Ledipasvir and Sofosbuvir, was assessed in hemodialysis (HD) patients diagnosed with hepatitis C virus (HCV) genotype 1 infection. As per observations, without any major adverse reactions, a combination therapy of Ledipasvir and Sofosbuvir on alternate days effectively afforded excellent sustained virological response (SVR12) rates, even in end stage renal disease (ESRD) patients, and was as safe as in other population groups.